Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

While academic specialists focus entirely on single diseases, community oncologists treat approximately 70% of cancer patients across constantly shifting malignancies. AI search and summary tools help general oncologists rapidly digest complex literature and filter the explosion of trial data between seeing patients with diverse diagnoses.

Related Insights

Beyond early discovery, LLMs deliver significant value in clinical trials. They accelerate timelines by automating months of post-trial documentation work. More strategically, they can improve trial success rates by analyzing genomic data to identify patient populations with a higher likelihood of responding to a treatment.

While acknowledging AI's current impact on productivity (e.g., doubling trial recruitment speed), Gilead views its ultimate transformative potential in supporting complex strategic decisions. This includes using AI to synthesize disparate data (genomic, literature, RWE) to identify the optimal disease indications for a new drug target.

AI's most significant impact won't be on broad population health management, but as a diagnostic and decision-support assistant for physicians. By analyzing an individual patient's risks and co-morbidities, AI can empower doctors to make better, earlier diagnoses, addressing the core problem of physicians lacking time for deep patient analysis.

AI is poised to revolutionize evidence synthesis by automating the grueling, multi-year process of systematic reviews. The ultimate goal is to enable anyone to get an accurate, near-instantaneous summary of the entire body of research on a specific question, effectively creating meta-analysis on demand.

By training on data across many cancer types ("pan-cancer"), AI models learn universal biological principles. This approach allows them to generalize learnings from large, common cancer datasets to significantly improve prediction accuracy for rare cancers, which often suffer from a lack of specific data for training effective models.

While doctors focused on the immediate, successful treatment, the speaker used AI to research and plan for the low-probability but high-impact event of a cancer relapse. This involved proactively identifying advanced diagnostics (ctDNA) and compiling a list of relevant clinical trials to act on immediately if needed.

The key takeaways from the major ASCO oncology conference are a continued strong push for Antibody-Drug Conjugates (ADCs), the rise of translational AI, and a strategic shift towards pan-tumor approaches that can address a wide panel of cancers rather than focusing on a single indication.

Recognizing that different specialists have unique information needs, Open Evidence develops distinct AI models for each role. For example, a surgeon's query about a procedure can surface peer-reviewed surgical videos—a feature irrelevant to a medical oncologist—thus enhancing the tool's utility through deep specialization.

An oncologist used ChatGPT to find the year's most important paper and it suggested a study on adjuvant exercise in colorectal cancer that wasn't on his list. This highlights AI's potential in research discovery and challenging expert assumptions.

The platform uses machine learning to combat the rapid obsolescence of medical guidelines. It systematically reviews every paragraph of ingested guidelines against new publications weekly, identifying and flagging specific sections that may be deprecated by more recent evidence, a critical function in fields like oncology.